Exicure CEO David Giljohann will present at the BTIG Virtual Biotechnology Conference on Monday, August 9, 2021 at 2:30pm ET: bit.ly/3ytTjeE

Exicure today reported financial results for the quarter ended June 30, 2021 and provided an update on corporate progress: bit.ly/3jHx3ry #DigitalDrugDesign

Dear Lawmakers President Biden Ron Wyden Nancy Pelosi Hundreds of us biotech investors, innovators, patient advocates, & NIH academics representing >40k US jobs, >600 drugs in trials, & >$200B invested propose solutions to affordability that preserve R&D. 1/ nopatientleftbehind.docsend.com/view/a6bxibzxy…

Exicure today announced participation in TIDES USA 2021 and the 17th Annual Meeting of the Oligonucleotide Therapeutics Society: bit.ly/39731bV #OTS #DigitalDrugDesign

Exicure CEO David Giljohann will present at the Benzinga Healthcare #SmallCap Conference on September 30, 2021, at 3:20 PM ET: bit.ly/3o1kzyE

Ataxia is a rare disease with symptoms that worsen over time making it hard to walk, talk and coordinate movement. Learn more: ataxia.org - Share our post to help others learn about Ataxia. #IAAD21

The Exicure team proudly sported blue and red in support of the initiatives by @Cure_FA and National Ataxia Foundation in raising awareness of #friedreichsataxia.

Exicure today announced presentations at the 17th International Congress on Neuronal Ceroid Lipofuscinosis (NCLs) and the International OligonucIeotides and Peptides Conference (IOPC) 2021: bit.ly/3AiJU9R #DigitalDrugDesign

We loved getting together for our quarterly Exicure Town Hall today! To learn more about our team, visit bit.ly/3uOpjsS.

Check out this Scientific American OpEd by Exicure Co-founder Chad A. Mirkin about the successes in #nanotechnology and #nanochemistry research over the past two decades. #DigitalDrugDesign

A special thank you from the Exicure team to FA Research Alliance for the invitation to present at this weekend’s Friedreich’s Ataxia Patient Symposium, a very important event in raising awareness & support to aid in the advancement of medical breakthroughs for #FA patients globally.

Interested in joining a team of dedicated scientists who are developing nucleic acid-based therapeutics to treat rare and severe genetic diseases and cancers? Exicure is #hiring! To learn more about our open positions, visit: bit.ly/3v6x25Q

At Exicure, we are proud to promote our flexible PTO policy which empowers our employees to balance work and life commitments!

Exicure today announced presentations at TIDES EU and Neuroscience 2021: bit.ly/3EoP1aT #DigitalDrugDesign #SfN21

Exicure today reported financial results for the third quarter 2021 and provided an update on corporate progress: bit.ly/3CxOrX8

Today we celebrated our team with an appreciation breakfast 🍳 Thank you to every Exicurian for your hard work and talent! #EmployeeAppreciationDay

Exicure today announced a poster presentation at #TIDESUSA 2022, May 9-12, 2022: bit.ly/3slI72S

Exicure remains proudly dedicated to discovering treatments for those affected by #HuntingtonsDisease. Together, we can break down stigmas, and work to bring hope to those living with HD and their families. #HDAwarenessMonth

Last week Team Exicure laced up our sneakers and hit the pavement for the annual Chicago J.P. Morgan Corporate Challenge! #JPMCC

Exicure today reported financial results for the quarter ended June 30, 2022 and provided an update on its business strategy and corporate progress: bit.ly/3SRryaw